Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 21, Issue 2, Pages 163-170Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458514538110
Keywords
Atrophy; multiple sclerosis; outcome measurement; progressive
Categories
Funding
- Betty and David Koetser Foundation for Brain Research
- Clinical Research Priority Program of the University of Zurich, Zurich, Switzerland
- Novartis
- Biogen Idec
- Teva
- Merz Pharmaceuticals
- Ipsen
- Esai
- Glaxo Smith Kline
- Roche
- MedImmune
- TFS
- Heidelberg Engineering
- Digna Biotech
- Neurotec Farma
- Biogen-IDEC
- NIH [R01 NS082347]
- German Research Council [DFG Exc 257]
- German Ministry of Education and Research (BMBF 'Competence Network Multiple Sclerosis')
- Sanofi-Aventis
- Genzyme
- Almirall
Ask authors/readers for more resources
Background: Retinal optical coherence tomography (OCT) permits quantification of retinal layer atrophy relevant to assessment of neurodegeneration in multiple sclerosis (MS). Measurement artefacts may limit the use of OCT to MS research. Objective: An expert task force convened with the aim to provide guidance on the use of validated quality control (QC) criteria for the use of OCT in MS research and clinical trials. Methods: A prospective multi-centre (n = 13) study. Peripapillary ring scan QC rating of an OCT training set (n = 50) was followed by a test set (n = 50). Inter-rater agreement was calculated using kappa statistics. Results were discussed at a round table after the assessment had taken place. Results: The inter-rater QC agreement was substantial (kappa = 0.7). Disagreement was found highest for judging signal strength (kappa = 0.40). Future steps to resolve these issues were discussed. Conclusion: Substantial agreement for QC assessment was achieved with aid of the OSCAR-IB criteria. The task force has developed a website for free online training and QC certification. The criteria may prove useful for future research and trials in MS using OCT as a secondary outcome measure in a multi-centre setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available